Article Details

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell ...

Retrieved on: 2023-01-05 14:07:48

Tags for this article:

Click the tags to see associated articles and topics

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell .... View article details on HISWAI: https://www.marketscreener.com/quote/stock/MAXCYTE-INC-26786499/news/MaxCyte-Signs-Strategic-Platform-License-with-Catamaran-Bio-to-Support-its-CAR-NK-Cell-Therapy-Progr-42666245/

Excerpt

MaxCyte, Inc., a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, ...

Article found on: www.marketscreener.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up